Collaborative Human Tissue Network (CHTN)

描述（由申请人提供）：生物病理学中心旨在促进慢性疾病和癌症的诊断和治疗的改进，最终目的是提高治愈率和减少治疗副作用。与这一使命相一致，儿科生物标本部的广泛和长期目标是继续集中精力为研究界提供科学相关的生物标本，包括改善获得高质量的儿科和青少年人类恶性，良性，患病和未涉及的生物标本。pCHTN旨在通过追求以下具体目标，直接促进和支持慢性病和癌症诊断和治疗方面的杰出研究： 1.根据适当的监管指南，通过在标准化采集、质量控制、储存和生物标本分发方面的持续努力和创新，为研究者群体提供高质量、科学相关的生物标本 2.通过确保适当跟踪生物标本谱系/处理/储存以及与现有人口统计学、临床、生物学、治疗和结局数据的联系，支持尖端研究的转化方面 3.通过促进稀有标本的联网，最大限度地提高有限资源的科学回报（例如，白血病、青少年癌症）以及启动新的知情同意程序，以促进与临床结果的联系 4.利用技术创新、最佳实践和研究者反馈，不断提高我们的运营能力、生物标本获取能力、研究者满意度以及我们保护的重要资源的管理能力 5.通过与COG的持续合作扩大儿科肿瘤采购 6.通过新的处理技术，更好地促进分子研究，提高组织的科学相关性

DESCRIPTION (provided by applicant): The Biopathology Center seeks to foster improvements in the diagnosis and treatment of chronic diseases and cancer, with the ultimate aim of increased cure rates and fewer treatment side effects. Consistent with this mission, the Pediatric Biospecimen Division's broad and long-term objective is to continue our focused efforts to provide scientifically-relevant biospecimens to the research community, including improved access to high-quality pediatric and adolescent human malignant, benign, diseased and uninvolved biospecimens. The pCHTN seeks to directly promote and support outstanding research in the diagnosis and treatment of chronic disease and cancer by pursuing the following specific aims: 1. To make high-quality, scientifically-relevant biospecimens available to the investigator community through continued efforts and innovations in standardized collection, quality control, storage, and biospecimen distribution under proper regulatory guidelines 2. To support translational aspects of cutting-edge research by ensuring appropriate tracking of biospecimen lineage/processing/storage as well as linkages to existing demographic, clinical, biological, treatment, and outcome data 3. To maximize scientific return on limited resources by promoting networking of rare specimens (e.g., leukemia, adolescent cancers) as well as initiating new informed consent procedures to facilitate linkage to clinical outcomes 4. To leverage innovations in technology, best practices, and investigator feedback to constantly improve our operational capabilities, access to biospecimens, investigator satisfaction, and stewardship of the vital resources we safeguard 5. To expand pediatric tumor procurement through continued partnership with COG 6. To enhance scientific-relevance of tissues through new processing technologies which better facilitate molecular research